These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2442437)

  • 21. Accessory factors involved in murine T cell activation. Distinct roles of interleukin 6, interleukin 1 and tumor necrosis factor.
    Vink A; Uyttenhove C; Wauters P; Van Snick J
    Eur J Immunol; 1990 Jan; 20(1):1-6. PubMed ID: 2407536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symposium on diagnosis and treatment of cancer. Recent progress.
    Jpn J Med; 1988 Feb; 27(1):96-112. PubMed ID: 2452911
    [No Abstract]   [Full Text] [Related]  

  • 23. Cytokines as endogenous pyrogens.
    Dinarello CA
    J Infect Dis; 1999 Mar; 179 Suppl 2():S294-304. PubMed ID: 10081499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological monitoring and clinical trials of biological response modifiers.
    Kopp WC; Holmlund JT; Urba WJ
    Cancer Chemother Biol Response Modif; 1994; 15():226-86. PubMed ID: 7540029
    [No Abstract]   [Full Text] [Related]  

  • 25. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages.
    Decker T; Lohmann-Matthes ML; Gifford GE
    J Immunol; 1987 Feb; 138(3):957-62. PubMed ID: 3492537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Negative regulators of in vivo erythropoiesis: interaction of IL-1 alpha and TNF-alpha and the lack of a strict requirement for T or NK cells for their activity.
    Johnson CS; Pourbohloul SC; Furmanski P
    Exp Hematol; 1991 Feb; 19(2):101-5. PubMed ID: 1991491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells.
    Mier JW; Dinarello CA; Atkins MB; Punsal PI; Perlmutter DH
    J Immunol; 1987 Aug; 139(4):1268-72. PubMed ID: 2440951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium periodate-induced T cell mitogenesis: an analysis of the requirement for Ia and IL 1.
    Smith LA; Cohen DA; Lachman LB; Kaplan AM
    J Immunol; 1985 Aug; 135(2):1137-44. PubMed ID: 2989361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biological immunomodulators in the treatment of cancer].
    Bello C; Richard C; Hermosa V; Iriondo A; Muruzábal MJ; Pérez Encinas M; Zubizarreta A
    Sangre (Barc); 1988 Apr; 33(2):132-43. PubMed ID: 2456623
    [No Abstract]   [Full Text] [Related]  

  • 30. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1.
    Ferrara JL; Abhyankar S; Gilliland DG
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1216-7. PubMed ID: 8442093
    [No Abstract]   [Full Text] [Related]  

  • 31. Analysis of a cytostatic lymphokine produced by incubation of lymphocytes with tumor cells: relationship to leukoregulin and distinction from recombinant lymphotoxin, recombinant tumor necrosis factor, and natural killer cytotoxic factor.
    Sayers TJ; Ransom JH; Denn AC; Herberman RB; Ortaldo JR
    J Immunol; 1986 Jul; 137(1):385-90. PubMed ID: 2423611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokines and immunological monitoring.
    Sosman JA; Sawhaney A
    Cancer Chemother Biol Response Modif; 1997; 17():217-86. PubMed ID: 9551216
    [No Abstract]   [Full Text] [Related]  

  • 33. A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor-alpha, interferon-gamma and interleukin 1.
    Geissler D; Gaggl S; Möst J; Greil R; Herold M; Dietrich M
    Eur J Immunol; 1990 Dec; 20(12):2591-6. PubMed ID: 1980110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mediators of the immune response and inflammation].
    Dayer JM
    Ther Umsch; 1986 Feb; 43(2):94-102. PubMed ID: 2421430
    [No Abstract]   [Full Text] [Related]  

  • 35. Recombinant tumor necrosis factor can induce interleukin 2 receptor expression and cytolytic activity in a rat x mouse T cell hybrid.
    Plaetinck G; Declercq W; Tavernier J; Nabholz M; Fiers W
    Eur J Immunol; 1987 Dec; 17(12):1835-8. PubMed ID: 3121359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokines and transcription factors.
    Muegge K; Durum SK
    Cytokine; 1990 Jan; 2(1):1-8. PubMed ID: 1716484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
    Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
    Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody.
    Palacios R
    Eur J Immunol; 1985 Jul; 15(7):645-51. PubMed ID: 3924633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interleukins: factors of intercellular communication].
    Ythier A
    Ann Biol Clin (Paris); 1985; 43(5):722-4. PubMed ID: 3937465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent trends in cancer treatment using cytokines].
    Urushizaki I
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):897-905. PubMed ID: 2471455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.